Biopharma Transcript

Innoviva, Inc. INVA

Nasdaq · Approved · EDGAR · Updated Nov 5, 2026

Innoviva, Inc. (Nasdaq: INVA) is a drug developer. Its lead program is marketed.

Upcoming catalysts

No catalyst is dated to the next 30 days or to an FDA action date.

Pipeline

Program	Indication	Modality	Stage
GIAPREZA (angiotensin II)	increasing blood pressure in adults with septic or other distributive shock	protein/peptide	Approved
XACDURO (sulbactam/durlobactam)	hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter	small molecule	Approved
XERAVA (eravacycline)	complicated intra-abdominal infections in adults	small molecule	Approved
ZEVTERA (ceftobiprole)	staphylococcus aureus bacteremia, right-sided endocarditis, acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia	small molecule	Approved
NUZOLVENCE (zoliflodacin)	uncomplicated urogenital gonorrhea in adults and adolescents	small molecule	Approved
RELVAR/BREO ELLIPTA (FF/VI)	COPD	small molecule	Approved
ANORO ELLIPTA (UMEC/VI)	COPD	small molecule	Approved

Recent results and decisions

Feb 25, 2026
approval FDA approved NUZOLVENCE (zoliflodacin) in December 2025 for uncomplicated urogenital gonorrhea in adults and pediatric patients 12 and older weighing at least 35 kg; commercialization planned 2H 2026.In December 2025, IST received U.S. Food and Drug Administration (FDA) approval of NUZOLVENCE® for the treatment of uncomplicated urogenital gonorrhea. Filing

For subscribers

Cash runway against each catalyst, with the company's own runway statement
Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
Expected move for each dated catalyst, from comparable past events
Phase 2 evidence behind each Phase 3 readout
Companies on the same target or class
Full catalyst list with filing sentences, deals, registered trials, Excel export

See plans Open in the tracker